Compare McKesson Corporation (MCK) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Quantumscape Corp — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Quantumscape Corp trades at $6.02 (market cap $3.62B). The key difference: McKesson Corporation is far larger — about 26.9× Quantumscape Corp's market cap, and McKesson Corporation pays a 0.39% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| MCK | QS | |
|---|---|---|
Market Cap | $97.35B | $3.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $18.44 |
52-Week Low | $659.01 | $5.86 |
Enterprise Value | $101.98B | $2.79B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
QuantumScape (QS) trades at $5.91, up 0.85% today, amid a bearish technical trend and negative profitability. The company reported a net loss of $435.05 million in 2025, with cash flow sustained by financing activities. Recent news highlights a joint research agreement with Honda, sparking investor interest in its solid-state battery technology.
The outlook remains speculative, hinging on successful commercialization of its battery technology. Key risks include persistent losses, high cash burn, and competitive pressures. Analyst sentiment is cautious, with no buy ratings and 72.7% hold recommendations, reflecting skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
